Targeting telomerase for cancer therapy | Oncogene
Telomere maintenance via telomerase reactivation is a nearly universal hallmark of cancer cells which enables replicative immortality. In contrast, telomerase activity is silenced in most adult somatic cells. Thus, telomerase represents an attractive target for highly selective cancer therapeutics. However, development of telomerase inhibitors has been challenging and thus far there are no clinically approved strategies exploiting this cancer target. The discovery of prevalent mutations in the TERT promoter region in many cancers and recent advances in telomerase biology has led to a renewed interest in targeting this enzyme. Here we discuss recent efforts targeting telomerase, including immunotherapies and direct telomerase inhibitors, as well as emerging approaches such as targeting TERT gene expression driven by TERT promoter mutations. We also address some of the challenges to telomerase-directed therapies including potential therapeutic resistance and considerations for future therapeutic applications and translation into the clinical setting. Although much work remains to be done, effective strategies targeting telomerase will have a transformative impact for cancer therapy and the prospect of clinically effective drugs is boosted by recent advances in structural models of human telomerase.
Subjects Cancer immunotherapy DNA damage response Melanoma Targeted therapies Abstract Telomere maintenance via telomerase reactivation is a nearly universal hallmark of cancer cells which enables replicative immortality. In contrast, telomerase activity is silenced in most adult somatic cells. Thus, telomerase represents an attractive target for highly selective cancer therapeutics. However, development of telomerase inhibitors has been challenging and thus far there are no clinically approved strategies exploiting this cancer target. The discovery of prevalent mutations in the TERT promoter
Explore this link on the map →saved by
related reading
- The current state and future directions of RNAi-based therapeutics | Nature Reviews Drug Discoverynature.com
- Nintil - The Longevity FAQnintil.com
- Immunotherapy for Cancer - NCIcancer.gov
- Has pancreatic cancer met its match?worksinprogress.co
- Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
- City of Hope scientists develop targeted chemotherapy able to kill all solid tumors in preclinical researchprnewswire.com
- Teaching an old dog new tricks: next-generation CAR T cells | British Journal of Cancernature.com
- Medicine's Endgamenotboring.co
- A primer on the current state of longevity researchowlposting.com
- Pancreatic Cancer - PMCncbi.nlm.nih.gov
- Cancer cells educate natural killer cells to a metastasis-promoting cell state - PMCpmc.ncbi.nlm.nih.gov
- The blood cancer that became solvableworksinprogress.news